VIVXF (Avivagen) ROE % Adjusted to Book Value: 0.00% (As of Jul. 2023)


What is Avivagen ROE % Adjusted to Book Value?

Avivagen VIVXF -99.00% ROE % Adjusted to Book Value is 0.00% as of Jul. 2023.

Avivagen's ROE % for the quarter that ended in Jul. 2023 was 0.00%. Avivagen's PB Ratio for the quarter that ended in Jul. 2023 was N/A. Avivagen's ROE % Adjusted to Book Value for the quarter that ended in Jul. 2023 was N/A.

Avivagen ROE % Adjusted to Book Value Related Terms

Avivagen ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Avivagen's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avivagen ROE % Adjusted to Book Value Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.83 0.00 0.00 0.00 0.00

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VIVXF vs DMKPQ, MJNE, ACORQ: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Avivagen's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avivagen ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avivagen's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Avivagen's ROE % Adjusted to Book Value falls into.


Avivagen ROE % Adjusted to Book Value Calculation

Avivagen's ROE % Adjusted to Book Value for the fiscal year that ended in Oct. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Avivagen's ROE % Adjusted to Book Value for the quarter that ended in Jul. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Avivagen (VIVXF) has a ROE % Adjusted to Book Value of 0.00% as of Jul. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Avivagen and its competitors.
Is Avivagen's ROE % Adjusted to Book Value too high?
Avivagen's current ROE % Adjusted to Book Value is 0.00%.
How does Avivagen's ROE % Adjusted to Book Value compare to DMKPQ and MJNE?
Avivagen's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Avivagen and its competitors. Avivagen's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avivagen stock overvalued right now?
Avivagen (VIVXF) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Avivagen (VIVXF), the current ROE % Adjusted to Book Value is 0.00% as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avivagen Business Description

Address 100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc OxC-beta technology is derived from Avivagen discoveries about Beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxCbeta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters.